NASDAQ:MTEM Molecular Templates (MTEM) Stock Price, News & Analysis → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Free MTEM Stock Alerts $1.59 -0.05 (-3.05%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$1.51▼$1.6950-Day Range$1.47▼$4.0352-Week Range$1.40▼$9.45Volume47,796 shsAverage Volume52,340 shsMarket Capitalization$8.54 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Molecular Templates alerts: Email Address Molecular Templates MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish6.97% of Float Sold ShortDividend StrengthN/ASustainability-0.93Upright™ Environmental ScoreNews SentimentN/AInsider TradingAcquiring Shares$587,500 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($2.70) to ($2.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.90 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Molecular Templates. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.97% of the float of Molecular Templates has been sold short.Short Interest Ratio / Days to CoverMolecular Templates has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Molecular Templates has recently increased by 508.28%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMolecular Templates does not currently pay a dividend.Dividend GrowthMolecular Templates does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMolecular Templates has received a 72.55% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Molecular Templates is -0.93. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Molecular Templates this week, compared to 0 articles on an average week.Search InterestOnly 2 people have searched for MTEM on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added Molecular Templates to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Molecular Templates insiders have bought more of their company's stock than they have sold. Specifically, they have bought $587,500.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders18.70% of the stock of Molecular Templates is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.47% of the stock of Molecular Templates is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Molecular Templates are expected to decrease in the coming year, from ($2.70) to ($2.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Molecular Templates is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Molecular Templates is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMolecular Templates has a P/B Ratio of 1.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About Molecular Templates Stock (NASDAQ:MTEM)Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company primarily develops therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.Read More MTEM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MTEM Stock News HeadlinesApril 5, 2024 | insidertrades.comTarget N. V. Biotech Acquires 250,000 Shares of Molecular Templates, Inc. (NASDAQ:MTEM) StockApril 11, 2024 | uk.investing.comMolecular Templates reports progress in cancer therapy trialApril 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 11, 2024 | msn.comMTEM Stock Earnings: Molecular Templates Beats EPS, Misses Revenue for Q4 2023April 9, 2024 | msn.comWhat's Going On With Molecular Templates Stock?April 9, 2024 | globenewswire.comMolecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology MechanismMarch 29, 2024 | msn.comMolecular Templates GAAP EPS of -$0.73, revenue of $7.02MMarch 29, 2024 | globenewswire.comMolecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business UpdateApril 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 28, 2024 | globenewswire.comMolecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase AgreementMarch 4, 2024 | finance.yahoo.comMolecular Templates, Inc. Provides Interim UpdateMarch 4, 2024 | globenewswire.comMolecular Templates, Inc. Provides Interim UpdateFebruary 8, 2024 | finance.yahoo.comMolecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences ConferenceDecember 6, 2023 | morningstar.comMolecular Templates Inc MTEMNovember 13, 2023 | msn.comMolecular Templates GAAP EPS of -$0.82 beats by $1.13, revenue of $6.8M beats by $4.34MNovember 13, 2023 | finance.yahoo.comMolecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business UpdateNovember 1, 2023 | finance.yahoo.comMolecular Templates to Participate in Upcoming Investor ConferencesSeptember 30, 2023 | seekingalpha.comMolecular Templates appoints Maurizio Voi as chief medical officerSeptember 30, 2023 | finanznachrichten.deMolecular Templates, Inc.: Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical OfficerSeptember 28, 2023 | finance.yahoo.comMolecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical OfficerAugust 31, 2023 | msn.comMolecular Templates (MTEM) Price Target Increased by 1400.00% to 38.25August 11, 2023 | finanznachrichten.deMolecular Templates, Inc.: Molecular Templates Announces 1-for-15 Reverse Stock SplitAugust 11, 2023 | finance.yahoo.comMolecular Templates Announces 1-for-15 Reverse Stock SplitAugust 10, 2023 | msn.comMolecular Templates GAAP EPS of -$0.19 beats by $0.15, revenue of $6.87M beats by $4.29MAugust 10, 2023 | finance.yahoo.comMolecular Templates, Inc. Reports Second Quarter 2023 Financial Results and Business UpdateAugust 4, 2023 | finance.yahoo.comAfter layoffs, Molecular Templates overhauls C-suiteJuly 13, 2023 | seekingalpha.comMolecular Templates launches $40M private placementSee More Headlines Receive MTEM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Molecular Templates and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/29/2024Today4/25/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:MTEM CUSIP88580720 CIK1183765 Webwww.mtem.com Phone(512) 869-1555Fax650-474-2529Employees111Year Founded2009Profitability EPS (Most Recent Fiscal Year)($1.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,120,000.00 Net Margins-14.18% Pretax Margin-14.20% Return on Equity-9,335.53% Return on Assets-20.51% Debt Debt-to-Equity RatioN/A Current Ratio0.97 Quick Ratio0.97 Sales & Book Value Annual Sales$57.31 million Price / Sales0.15 Cash FlowN/A Price / Cash FlowN/A Book Value$0.78 per share Price / Book2.05Miscellaneous Outstanding Shares5,370,000Free Float4,369,000Market Cap$8.59 million OptionableNo Data Beta1.15 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Eric E. Poma Ph.D. (Age 52)CEO, Chief Scientific Officer & Director Comp: $923.34kMs. Jason S Kim (Age 49)President, CFO, Treasurer & Principal Accounting Officer Comp: $639.85kMs. Kristen Quigley B.A. (Age 53)Chief Operating Officer Dr. Grace KimChief Strategy Officer & Head of IRDr. Joseph Phillips Ph.D.Senior VP & Head of CMC DevelopmentDr. Maurizio Voi M.D. (Age 66)Chief Medical Officer More ExecutivesKey CompetitorsVirios TherapeuticsNASDAQ:VIRINuCanaNASDAQ:NCNACyclerion TherapeuticsNASDAQ:CYCNHepion PharmaceuticalsNASDAQ:HEPAUniverse PharmaceuticalsNYSE:UPCView All CompetitorsInsiders & InstitutionsTarget N V BiotechBought 250,000 shares on 4/2/2024Total: $587,500.00 ($2.35/share)Monashee Investment Management LLCSold 20,000 shares on 2/12/2024Ownership: 2.269%Target N V BiotechBought 283,687 shares on 7/17/2023Total: $2.00 M ($7.05/share)View All Insider TransactionsView All Institutional Transactions MTEM Stock Analysis - Frequently Asked Questions How have MTEM shares performed in 2024? Molecular Templates' stock was trading at $3.73 at the beginning of the year. Since then, MTEM shares have decreased by 58.6% and is now trading at $1.5450. View the best growth stocks for 2024 here. Are investors shorting Molecular Templates? Molecular Templates saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 205,600 shares, an increase of 508.3% from the March 31st total of 33,800 shares. Based on an average trading volume of 61,600 shares, the days-to-cover ratio is currently 3.3 days. Currently, 7.0% of the company's stock are sold short. View Molecular Templates' Short Interest. When is Molecular Templates' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our MTEM earnings forecast. How were Molecular Templates' earnings last quarter? Molecular Templates, Inc. (NASDAQ:MTEM) released its earnings results on Friday, March, 29th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.10) by $1.37. The biotechnology company earned $7.02 million during the quarter. Molecular Templates had a negative net margin of 14.18% and a negative trailing twelve-month return on equity of 9,335.53%. When did Molecular Templates' stock split? Molecular Templates's stock reverse split before market open on Monday, August 14th 2023. The 1-15 reverse split was announced on Friday, August 11th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Molecular Templates own? Based on aggregate information from My MarketBeat watchlists, some companies that other Molecular Templates investors own include ZIOPHARM Oncology (ZIOP), Novavax (NVAX), Gilead Sciences (GILD), TG Therapeutics (TGTX), Pfizer (PFE), Synergy Pharmaceuticals (SGYP), Amarin (AMRN), Corbus Pharmaceuticals (CRBP) and Exelixis (EXEL). How do I buy shares of Molecular Templates? Shares of MTEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MTEM) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss RatingsFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Molecular Templates, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
